{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:27Z","timestamp":1778780127404,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41416-019-0443-4","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T23:03:56Z","timestamp":1554332636000},"page":"896-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial"],"prefix":"10.1038","volume":"120","author":[{"given":"Eric","family":"Assenat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges-Philippe","family":"Pageaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Th\u00e9zenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Peron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"B\u00e9couarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ramdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Poujol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"de Forges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"443_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012v1.0, Cancer Incidence and mortality Worldwide: IARC CancerBase No11 [Internet] [cit\u00e9 13 oct 2017]. Disponible sur: \n                    http:\/\/publications.iarc.fr\/Databases\/Iarc-Cancerbases\/Globocan-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1-0-2012"},{"key":"443_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1743-422X-9-16","volume":"9","author":"JY Zhou","year":"2012","unstructured":"Zhou, J.-Y., Zhang, L., Li, L., Gu, G.-Y., Zhou, Y.-H. & Chen, J.-H. High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study. Virol. J. 9, 16 (2012).","journal-title":"Virol. J."},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","volume":"62","author":"CL Lai","year":"1988","unstructured":"Lai, C. L., Wu, P. C., Chan, G. C., Lok, A. S. & Lin, H. J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62, 479\u201383 (1988).","journal-title":"Cancer"},{"key":"443_CR4","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2006.08.4046","volume":"25","author":"RG Gish","year":"2007","unstructured":"Gish, R. G., Porta, C., Lazar, L., Ruff, P., Feld, R., Croitoru, A. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069\u201375 (2007).","journal-title":"J. Clin. Oncol."},{"key":"443_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u201390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"443_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"443_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ejca.2014.12.005","volume":"51","author":"A Hollebecque","year":"2015","unstructured":"Hollebecque, A., Malka, D., Fert\u00e9, C., Ducreux, M. & Boige, V. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur. J. Cancer 51, 327\u201339 (2015).","journal-title":"Eur. J. Cancer"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u201373 (2018).","journal-title":"Lancet"},{"issue":"Suppl 7","key":"443_CR9","doi-asserted-by":"publisher","first-page":"vii41","DOI":"10.1093\/annonc\/mds225","volume":"23","author":"C Verslype","year":"2012","unstructured":"Verslype, C., Rosmorduc, O. & Rougier, P., ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii41\u201348 (2012).","journal-title":"Ann. Oncol."},{"key":"443_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"443_CR11","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2018.36.15_suppl.4003","volume":"36","author":"AX Zhu","year":"2018","unstructured":"Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M. et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J. Clin. Oncol. 36(15_suppl), 4003\u20134003 (2018).","journal-title":"J. Clin. Oncol."},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u2013502 (2017).","journal-title":"Lancet"},{"key":"443_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1634\/theoncologist.2014-0190","volume":"19","author":"S Qin","year":"2014","unstructured":"Qin, S., Cheng, Y., Liang, J., Shen, L., Bai, Y., Li, J. et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 19, 1169\u201378 (2014).","journal-title":"Oncologist"},{"key":"443_CR14","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6603956","volume":"97","author":"V Boige","year":"2007","unstructured":"Boige, V., Raoul, J.-L., Pignon, J.-P., Bouch\u00e9, O., Blanc, J.-F., Dahan, L. et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br. J. Cancer 97, 862\u20137 (2007).","journal-title":"Br. J. Cancer"},{"key":"443_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/cncr.22532","volume":"109","author":"S Louafi","year":"2007","unstructured":"Louafi, S., Boige, V., Ducreux, M., Bonyhay, L., Mansourbakht, T., de Baere, T. et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109, 1384\u201390 (2007).","journal-title":"Cancer"},{"key":"443_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/COC.0b013e318162f57d","volume":"31","author":"Y Yen","year":"2008","unstructured":"Yen, Y., Lim, D. W., Chung, V., Morgan, R. J., Leong, L. A., Shibata, S. I. et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am. J. Clin. Oncol. 31, 317\u201322 (2008).","journal-title":"Am. J. Clin. Oncol."},{"key":"443_CR17","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cncr.11869","volume":"98","author":"J Ta\u00efeb","year":"2003","unstructured":"Ta\u00efeb, J., Bonyhay, L., Golli, L., Ducreux, M., Boleslawski, E., Tigaud, J.-M. et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 98, 2664\u201370 (2003).","journal-title":"Cancer"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/cncr.23489","volume":"112","author":"A Asnacios","year":"2008","unstructured":"Asnacios, A., Fartoux, L., Romano, O., Tesmoingt, C., Louafi, S. S., Mansoubakht, T. et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 112, 2733\u20139 (2008).","journal-title":"Cancer"},{"key":"443_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2012.09.006","volume":"58","author":"A Zaanan","year":"2013","unstructured":"Zaanan, A., Williet, N., Hebbar, M., Dabakuyo, T. S., Fartoux, L., Mansourbakht, T. et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J. Hepatol. 58, 81\u20138 (2013).","journal-title":"J. Hepatol."},{"key":"443_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jhep.2010.06.015","volume":"54","author":"C Tournoux-Facon","year":"2011","unstructured":"Tournoux-Facon, C., Paoletti, X., Barbare, J.-C., Bouch\u00e9, O., Rougier, P., Dahan, L. et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J. Hepatol. 54, 108\u201314 (2011).","journal-title":"J. Hepatol."},{"key":"443_CR21","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. J. Am. Med Assoc. 304, 2154\u201360 (2010).","journal-title":"J. Am. Med Assoc."},{"issue":"4_suppl","key":"443_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/jco.2016.34.4_suppl.192","volume":"34","author":"GK Abou-Alfa","year":"2016","unstructured":"Abou-Alfa, G. K., Niedzwieski, D., Knox, J. J., Kaubisch, A., Posey, J., Tan, B. R. et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J. Clin. Oncol. 34(4_suppl), 192\u2013192 (2016).","journal-title":"J. Clin. Oncol."},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","volume":"31","author":"AL Cheng","year":"2013","unstructured":"Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067\u201375 (2013).","journal-title":"J. Clin. Oncol."},{"key":"443_CR24","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","volume":"31","author":"PJ Johnson","year":"2013","unstructured":"Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517\u201324 (2013).","journal-title":"J. Clin. Oncol."},{"key":"443_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","volume":"33","author":"C Cainap","year":"2015","unstructured":"Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y. et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 33, 172\u20139 (2015).","journal-title":"J. Clin. Oncol."},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57, 821\u20139 (2012).","journal-title":"J. Hepatol."},{"key":"443_CR27","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s10147-015-0796-5","volume":"20","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Yue, H., Xu, S., Wang, F., Ma, N., Li, K. et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int. J. Clin. Oncol. 20, 952\u20139 (2015).","journal-title":"Int. J. Clin. Oncol."},{"key":"443_CR28","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P. et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017).","journal-title":"Oncoimmunology"},{"key":"443_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro, B., Gomez-Martin, C., de la Mata, M., I\u00f1arrairaegui, M., Garralda, E., Barrera, P. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59, 81\u20138 (2013).","journal-title":"J. Hepatol."},{"key":"443_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jhep.2016.12.009","volume":"66","author":"MF Sprinzl","year":"2017","unstructured":"Sprinzl, M. F. & Galle, P. R. Current progress in immunotherapy of hepatocellular carcinoma. J. Hepatol. 66, 482\u20134 (2017).","journal-title":"J. Hepatol."},{"key":"443_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343\u201354 (2016).","journal-title":"Immunity"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0443-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:40Z","timestamp":1684616680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["443"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0443-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"6 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.A. reports personal fees from Bayer, Sirtex, Novartis, Ipsen and Sanofi, and travel and expenses from Bayer and Ipsen, outside the submitted work. P.M. reports personal fees from Bayer outside the submitted work. J.F.B. reports personal fees from Bayer, outside the submitted work. O.B. reports personal fees (board and speaker) from Amgen, Roche, Merck Sereno, Bayer, and from Pierre Fabre, Novartis and Lilly, outside the submitted work. All other authors have nothing to disclose regarding the present study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients signed an informed consent before entering the study. The study protocol was approved by an ethical review board (Comit\u00e9 de Protection des Personnes Sud M\u00e9diterrann\u00e9e IV, September 2<sup>nd<\/sup>, 2008; EudraCT number: 2008-000123-26) and was conducted in accordance with the good clinical practice and Declaration of Helsinki guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}